<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240548</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-BC-1/2016</org_study_id>
    <nct_id>NCT04240548</nct_id>
  </id_info>
  <brief_title>Radiation Therapy for ypN0 Breast Cancer</brief_title>
  <official_title>Role of Regional Nodal Irradiation in Node Positive Breast Cancer Patients With ypN0 After Preoperative Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III randomized study comparing regional nodal irradiation vs. no irradiation
      for breast cancer patients presenting with node positive disease who turns into node negative
      after preoperative chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional Nodal Failure ( axillary, internal mammary or supraclavicular recurrences )</measure>
    <time_frame>time from randomization till supraclavicular, axillary or internal mammary recurrence, assessed up to 10 years</time_frame>
    <description>axillary, internal mammary or supraclavicular recurrences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free survival</measure>
    <time_frame>Time from randomization until local, regional or distant recurrence, assessed up to 10 years</time_frame>
    <description>local recurrence, regional recurrence, distant recurrence, contralateral breast recurrence and second primary cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from randomization till death from any cause, assessed up to 10 years</time_frame>
    <description>death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Failure</measure>
    <time_frame>from time of randomization until chest wall recurrence post mastectomy or In Breast Tumor Recurrence post lumpectomy, assessed up to 10 years</time_frame>
    <description>chest wall recurrence post mastectomy or In Breast Tumor Recurrence post lumpectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm: A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm: B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>chest wall or whole breast only irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Regional Nodal Irradiation</intervention_name>
    <arm_group_label>Arm: A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO performance status 0-1

          -  Invasive Breast Cancer with cT1-3 cN1-2 at time of diagnosis

          -  Axillary nodal involvement can be detected using, clinical examination, ultrasound, CT
             scan or PET scan

          -  Pathologic confirmation using, FNAC, core biopsy or excisional biopsy

          -  ER, PR, Her2 neu and Ki67 status should be available for all patients

          -  All patients should have received standard preoperative chemotherapy prior to surgery

          -  At the time of surgery, all patients should have axillary clearance with at least 6
             nodes harvested from the axilla

          -  Patients who have undergone mastectomy or lumpectomy with negative margins with ypN0,
             ypN0(+i) or ypN0(+mol) are eligible for randomization

        Exclusion Criteria:

          -  Poor performance status

          -  Definitive clinical or radiologic evidence of metastatic disease

          -  T4 tumors including inflammatory breast cancer

          -  N3 disease detected clinically or by imaging

          -  Patients with histologically positive axillary nodes after preoperative chemotherapy

          -  Positive surgical margin after definitive surgery

          -  Previous ipsilateral or contralateral breast cancer

          -  Previous chest wall or breast irradiation

          -  Second primary cancer

          -  Active connective tissue disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Rimoun Ramsis Anis Boutrus</investigator_full_name>
    <investigator_title>Lecturer of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>regional nodal irradiation</keyword>
  <keyword>preoperative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

